Australian clinical stage cell therapy firm Chimeric Therapeutics' (ASX:CHM) Phase 1B trial of its CHM 1101 therapy for glioblastoma has had an abstract chosen for presentation at the American Society of Clinical Oncology.
The abstract will highlight the clinical trial design and objectives for the trial at the Annual Meeting of the American Society of Clinical Oncology being held in June in Chicago, Illinois.
Chimeric Therapeutics says its Chimeric Antigen Receptor therapy uses the peptide component of scorpion venom, chlorotoxin (CLTX), as the tumor-targeting component.
In preclinical trials, CLTX has demonstrated potential for binding with glioblastoma cells and exhibited potent antitumor activity against the disease.